GlaxoSmithKline, the world's second-largest drugmaker, wants to collaborate with scientists in China, where it's building a facility to research and develop medicines for Alzheimer's and other degenerative diseases.
Glaxo is spending an initial $40 million on the Shanghai facility, it's first in China, where it plans to hire as many as 50 scientists, the London-based company said in a statement this week. More than 1,000 people may be employed within a decade at the center, which aims to work with local researchers on treatments for Parkinson's disease and multiple sclerosis.
``Shanghai has great potential among its scientists in medical research,'' Grace Xu, a Glaxo spokeswoman in Shanghai said in a telephone interview today. Company executives ``have visited Shanghai several times to discuss collaboration with local universities and some research institutes,'' she said.
Jingwu Zang, a former director of the Institute of Health and Science at Shanghai Jiao Tong University's medical school, was hired last month to head the center.
More at Bloomberg
No comments:
Post a Comment